Wound debridement |
- |
Disruption of the mucopolysaccharide matrix. Destabilizes the biofilm's architecture promotes bacterial detachment increases antimicrobial delivery |
- |
Many promote the inoculation of infection in deeper tissues |
- |
Chronic wounds |
- |
Mehanical |
- |
- |
Enzymatic |
- |
- |
Biological |
- |
Topical or systemic antibiotic theraphy |
- |
Low cost |
- |
Development of antibiotic resistance |
- |
Acute wounds |
- |
Fluoroquinolones, tetracycline,rifampin, daptomycin, and vancomycin |
- |
Efficient in acute infections |
- |
Development of antibiotic tolerance in biofilms |
- |
Eradication of planktonic bacteria |
- |
Microbial inbalance (target both pathogenic and beneficial bacteria) |
- |
Biofilm disruption |
- |
Multiple side effects |
Topical antiseptic therapy |
- |
Cytotoxic toward bacteria, fungi, and others microorganisms |
- |
Might damage host cell and adversely affect wound healing |
- |
Acute wounds |
- |
Povidone-iodine, chlorhexidine, hedrogen, peroxide, boric acid, silver Sulfadiazine or nitrate, sodium hypochlorite, mafenide acetate, octenidine dihydrochloride, Ployhexamethylene biguanide (ployhexanide) |
- |
Chronic wounds |
Bacteriophage therapy |
- |
May be efficient against polymicrobial bio film-mediated infections |
- |
Biological-associated risks |
- |
Chronic wounds |
- |
Monophage preparations (staphylococcal bacteriophages, pyocianic bacteriophages) |
- |
Very specific for targeted bacterial species |
- |
Unknown side effects |
- |
Multiple phage preparations |
- |
High production costs |
- |
Applied in low amount as a topic treatment |
Antimicrobial peptides |
- |
Antimicrobial properties |
- |
Used in small amounts |
- |
Chromic Wounds |
- |
Defensins, magainins, cecropins |
- |
Low stability |
- |
Increased volatility |
Probiotic theraphy |
- |
Accelerates wound healing |
- |
Insufficient data |
- |
Chromic Wounds |
- |
Lactobacillus plantarum |
- |
Prevents wound colonization, biofilm developent |
- |
Interferes with the quorum sensing of p. aeruginoa |